Ovarian Cancer News & Features
A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.
Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.
Chronic inactivity has been linked to greater risk for ovarian cancer.
The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.
Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.
Excess abdominal fat in overweight and obese women could interfere with detection of early symptoms of ovarian cancer, and this may contribute to the higher risk of death from ovarian cancer in African American women compared with white women.
Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant
Prior oral contraceptive use is associated with reduced risk for ovarian cancer among women of all ages; however, risk reductions associated with childbirth wane as women age
Risk-reducing mastectomy (RRM) can increase life expectancy and be cost effective in women up to age 60 years with ovarian cancer as carriers of a BRCA mutation.
Ovarian Cancer Clinical Trials
- Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma
- How Can We Have a Cancer Cure Moonshot if We're Short of Fuel?
- High-Fat Mediterranean Diet Can Protect Against Cancer
- Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation Carriers
- HPV Vaccination Program Reduces Cervical Cell Anomalies in Young Women
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Helical APBI Delivers Targeted Dose of Adjuvant Radiation Treatment for Breast Cancer
- Cancer Risk Higher in Patients With Heart Failure After a First Heart Attack
- Routine Pap Smears Improve Cervical Cancer Risk in Women Older Than 65 Years
- Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer
- Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|